BR0316868A - Processo para a produção de pró-medicamentos de nucleosìdeo-3' - Google Patents

Processo para a produção de pró-medicamentos de nucleosìdeo-3'

Info

Publication number
BR0316868A
BR0316868A BR0316868-9A BR0316868A BR0316868A BR 0316868 A BR0316868 A BR 0316868A BR 0316868 A BR0316868 A BR 0316868A BR 0316868 A BR0316868 A BR 0316868A
Authority
BR
Brazil
Prior art keywords
production
nucleoside
prodrugs
nucleosidide
acylation
Prior art date
Application number
BR0316868-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Storer
Adel Moussa
Steven Mathieu
Original Assignee
Idenix Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Cayman Ltd filed Critical Idenix Cayman Ltd
Publication of BR0316868A publication Critical patent/BR0316868A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BR0316868-9A 2002-12-23 2003-12-23 Processo para a produção de pró-medicamentos de nucleosìdeo-3' BR0316868A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43615002P 2002-12-23 2002-12-23
PCT/US2003/041603 WO2004058792A1 (en) 2002-12-23 2003-12-23 Process for the production of 3'-nucleoside prodrugs

Publications (1)

Publication Number Publication Date
BR0316868A true BR0316868A (pt) 2005-10-25

Family

ID=32682350

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316868-9A BR0316868A (pt) 2002-12-23 2003-12-23 Processo para a produção de pró-medicamentos de nucleosìdeo-3'

Country Status (16)

Country Link
US (1) US20040181051A1 (https=)
EP (1) EP1575971A4 (https=)
JP (1) JP2006514038A (https=)
KR (1) KR20050110611A (https=)
CN (1) CN100335492C (https=)
AU (1) AU2003300434A1 (https=)
BR (1) BR0316868A (https=)
CA (1) CA2511616A1 (https=)
IL (1) IL169314A0 (https=)
MX (1) MXPA05006865A (https=)
NO (1) NO20053557L (https=)
NZ (1) NZ540913A (https=)
PL (1) PL377608A1 (https=)
RU (1) RU2005123395A (https=)
WO (1) WO2004058792A1 (https=)
ZA (1) ZA200505040B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
US7595390B2 (en) * 2003-04-28 2009-09-29 Novartis Ag Industrially scalable nucleoside synthesis
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
JP5089395B2 (ja) * 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
AU2005322242B2 (en) * 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
EP1863500A2 (en) 2005-03-29 2007-12-12 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
WO2007039413A2 (en) * 2005-09-22 2007-04-12 F. Hoffmann-La Roche Ag Selective o-acylation of nucleosides
WO2007095269A2 (en) * 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
JP2009532411A (ja) 2006-04-04 2009-09-10 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖ治療のための３’，５’−ジ−ｏ−アシル化ヌクレオシド
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
SG172921A1 (en) 2009-01-09 2011-08-29 Univ Cardiff Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
KR20210096160A (ko) * 2018-11-25 2021-08-04 티엔티 메디칼 코포레이션 젬시타빈의 경구 활성 전구약물

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562543B1 (fr) * 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
CA2083961A1 (en) * 1990-05-29 1991-11-30 Henk Van Den Bosch Synthesis of glycerol di- and triphosphate derivatives
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5157027A (en) * 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5696277A (en) * 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
IL129126A0 (en) * 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
KR100719606B1 (ko) * 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CZ298681B6 (cs) * 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
WO2001018013A1 (en) * 1999-09-08 2001-03-15 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
US6566365B1 (en) * 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
CA2396713A1 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
CN1427722A (zh) * 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
EP1964569A3 (en) * 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) * 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
NZ575481A (en) * 2000-10-18 2010-10-29 Pharmasset Inc Simultaneous quantification of nucleic acids in diseased cells
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2002057425A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
RU2004128943A (ru) * 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
US7247621B2 (en) * 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
AU2003232071A1 (en) * 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
PL374781A1 (en) * 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA04012779A (es) * 2002-06-28 2005-08-19 Idenix Cayman Ltd Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
AU2003279797B2 (en) * 2002-09-30 2009-10-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
HUE033832T2 (en) * 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
RU2005121904A (ru) * 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов

Also Published As

Publication number Publication date
MXPA05006865A (es) 2005-12-12
KR20050110611A (ko) 2005-11-23
PL377608A1 (pl) 2006-02-06
CA2511616A1 (en) 2004-07-15
US20040181051A1 (en) 2004-09-16
IL169314A0 (en) 2007-07-04
EP1575971A4 (en) 2008-03-05
ZA200505040B (en) 2006-04-26
JP2006514038A (ja) 2006-04-27
AU2003300434A1 (en) 2004-07-22
CN100335492C (zh) 2007-09-05
RU2005123395A (ru) 2006-01-27
NZ540913A (en) 2008-02-29
WO2004058792A1 (en) 2004-07-15
NO20053557L (no) 2005-09-08
CN1751058A (zh) 2006-03-22
EP1575971A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
BR0316868A (pt) Processo para a produção de pró-medicamentos de nucleosìdeo-3'
DK1523489T3 (da) Modificerede 2'- og 3'-nukleosidprodrugs til behandling af flaviridae-infektioner
NZ543867A (en) Modified fluorinated nucleoside analogues
BR0316407A (pt) Derivados de nucleosìdeo antiviral
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
WO2003062255A3 (en) Sugar modified nucleosides as viral replication inhibitors
ES2105698T3 (es) Oligonucleotidos modificados con 7-deazapurina.
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
NO20060979L (no) Nye tricykliske nukleosider eller nukleotider som terapeutiske midler
AP2005003213A0 (en) 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
BR0311612A (pt) Catalisador orgânico com solubilidade elevada, composição e aditivo de limpeza contendo o mesmo, processo de fabricação do mesmo, processo para a produção de sulfatos cìclicos e processo de limpeza de superfìcies ou tecidos
DK1178999T3 (da) L-RIBO-LNA-analoger
GT200100022A (es) Derivados de nicotinamida benzocondensada-heterociclilo utiles como inhibidores selectivos de las isozimas pde4.
BR9915818A (pt) Processo e composições para a prevenção de tolerância a medicações
MY144616A (en) Substituted dihydroquinazolines
BR9915636A (pt) Método para promover secreções cervicais e vaginais
BR0315169A (pt) Referência cruzada a pedidos de patente relacionados
BR9907882A (pt) Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
BRPI0415209A (pt) derivados de tetraidronaftaleno, processo para a produção deles e seu emprego como agentes antiinflamatórios
BR0212925A (pt) Derivados de idol como inibidores de cox ii
EP1545510A4 (en) SUBSTITUTED PHENYLINDOLE FOR THE TREATMENT OF HIV
BR0206828A (pt) Composição, processo, para produzir a mesma, polìmero acrìlico, processo para produzir uma fibra polimérica, uso de um polìmero acrìlico, fibra, e, uso de uma composição
BR0100982A (pt) Processo para a preparação de derivados deresorcinol
BRPI0400375A (pt) Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo
BR0108771A (pt) Processos para a preparação de um triéster de fosforotioato, e de oligonucleotìdeo desprotegido, fosforotioato de oligonucleotìdeo, ou oligonucleotìdeo/fosforotioato de oligonucleotìdeo mistos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADE(S),

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.